Adagene And 2 Other Promising Penny Stocks To Watch

As the United States market navigates a period of volatility amid tariff announcements and economic uncertainties, investors are keenly observing opportunities that may arise in less conventional areas. Penny stocks, despite their somewhat outdated moniker, remain an intriguing segment for those interested in smaller or newer companies with potential for growth. These stocks can offer significant value when backed by strong financials, and this article explores three such promising candidates that could appeal to investors seeking hidden gems with long-term potential.

Top 10 Penny Stocks In The United States

Click here to see the full list of 757 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Adagene (NasdaqGM:ADAG)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Adagene Inc. is a clinical stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancer treatment, with a market cap of approximately $71.61 million.

Operations: The company's revenue is derived entirely from its pharmaceuticals segment, amounting to $0.10 million.

Market Cap: $71.61M

Adagene Inc., a clinical-stage biotechnology firm, remains pre-revenue with earnings of US$0.10 million and a market cap of US$71.61 million. Despite its unprofitability and increased net loss to US$33.42 million in 2024, the company is advancing its ADG126 program for colorectal cancer, leveraging its SAFEbody technology to enhance safety and efficacy in tumor-specific targeting. Adagene's short-term assets exceed liabilities, providing financial stability amid high volatility (10%). The company has sufficient cash runway for over a year while forecasting revenue growth at 39.6% annually despite anticipated earnings decline by 14.4% per year over three years.

• Unlock comprehensive insights into our analysis of Adagene stock in this financial health report.
• Examine Adagene's earnings growth report to understand how analysts expect it to perform.

BARK (NYSE:BARK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: BARK Inc. is a dog-centric company offering products, services, and content for dogs, with a market cap of $243.13 million.

Operations: The company's revenue is generated from two main segments: Commerce, which accounts for $65.13 million, and Direct to Consumer, contributing $425.12 million.

Market Cap: $243.13M

BARK Inc., with a market cap of US$243.13 million, is navigating the penny stock landscape with a focus on improving financial stability and shareholder value. Despite being unprofitable, BARK's short-term assets of US$229.4 million comfortably cover both short-term (US$140.5 million) and long-term liabilities (US$38.6 million), indicating solid financial footing. The company has initiated a share repurchase program worth up to US$4 million, signifying confidence in its future prospects despite recent net losses increasing to US$11.51 million for Q3 2025 from the previous year’s loss of US$10.11 million, while revenue showed slight growth to US$126.45 million.

• Get an in-depth perspective on BARK's performance by reading our balance sheet health report here.
• Explore BARK's analyst forecasts in our growth report.

BioRegenx (OTCPK:BRGX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: BioRegenx, Inc. operates a social media content management platform and has a market cap of $19.23 million.

Operations: The company's revenue segment includes Diagnostic Kits / Equipment, which reported -$0.83 million.

Market Cap: $19.23M

BioRegenx, Inc., with a market cap of US$19.23 million, is pre-revenue and faces financial challenges typical in the penny stock domain. The company has reported negative earnings growth over the past five years, with losses increasing by 1.1% annually. Recent events include delayed SEC filings and executive changes, raising concerns about governance stability. Despite its unprofitability, BioRegenx maintains a satisfactory net debt to equity ratio of 15.4% and has sufficient cash runway for over three years if current positive free cash flow levels are maintained. However, its share price remains highly volatile amidst these uncertainties.

• Click here to discover the nuances of BioRegenx with our detailed analytical financial health report.
• Gain insights into BioRegenx's historical outcomes by reviewing our past performance report.

Taking Advantage

• Discover the full array of 757 US Penny Stocks right here.
• Searching for a Fresh Perspective? The latest GPUs need a type of rare earth metal called Terbium and there are only 21 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com